Antonio Segovia-Zafra

Mr. Antonio Segovia-Zafra

Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Madrid, Spain
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2021
Verified
Open access
Antonio Segovia-ZafraAntonio Segovia-Zafra
Antonio Segovia-Zafra
DSDaniel Enrique Di Zeo Sánchez
Daniel Enrique Di Zeo Sánchez
CLCarlos López-Gómez
Carlos López-Gómez
ZPZeus Pérez-Valdés
Zeus Pérez-Valdés
EGEduardo García-Fuentes
Eduardo García-Fuentes
Marina Villanueva-PazMarina Villanueva-Paz
Marina Villanueva-Paz
Idiosyncratic drug-induced liver injury (iDILI) encompasses the unexpected harms that prescription and non-prescription drugs, herbal and dietary supplements can cause to the liver. iDILI remains a major public health problem and a major cause of drug attrition. Given the lack of biomarkers for iDILI prediction, diagnosis and prognosis, searching new models to predict and study mechanisms of iDILI is necessary. One of the major limitations of iDILI preclinical assessment has been the lack of correlation between the markers of hepatotoxicity inanimal toxicological studies and clinically significant iDILI. Thus, major advances in the understanding of iDILI susceptibility and pathogenesis have come from the study of well-phenotyped iDILI patients. However, there are many gaps for explaining all the complexity of iDILI susceptibility and mechanisms. Therefore, there is a need to optimize preclinical human in vitro models to reduce the risk of iDILI during drug development. Here, the current experimental models and the future directions in iDILI modelling are thoroughly discussed, focusing on the human cellular models available to study the pathophysiological mechanisms of the disease and the most used in vivo animal iDILI models. We also comment about in silico approaches and the increasing relevance of patient-derived cellular models.

2 May 2024 in Journal of Hepatology
Verified
Journal Article
Open access
Antonio Segovia-ZafraAntonio Segovia-Zafra
Antonio Segovia-Zafra
Marina Villanueva-PazMarina Villanueva-Paz
Marina Villanueva-Paz
ASAna Serras
Ana Serras
GMGonzalo Matilla-Cabello
Gonzalo Matilla-Cabello
AGAna Bodoque García
Ana Bodoque García
LNLeonard Joseph Nelson
Leonard Joseph Nelson
Idiosyncratic drug-induced liver injury (DILI) is a complex and unpredictable event caused by drugs, and herbal or dietary supplements. Early identification of human hepatotoxicity at preclinical stages remains a major challenge, in which the selection of validated in vitro systems and test drugs has a significant impact. In this systematic review, we analyzed the compounds used in hepatotoxicity assays and established a list of DILI-positive and -negative control drugs for validation of in vitro models of DILI, supported by literature and clinical evidence and endorsed by an expert committee from the COST Action ProEuroDILI Network (CA17112). Following 2020 PRISMA guidelines, original research articles focusing on DILI which used in vitro human models and performed at least one hepatotoxicity assay with positive and negative control compounds, were included. Bias of the studies was assessed by a modified 'Toxicological Data Reliability Assessment Tool'. A total of 51 studies (out of 2,936) met the inclusion criteria, with 30 categorized as reliable without restrictions. Although there was a broad consensus on positive compounds, the selection of negative compounds lacked clarity. 2D monoculture, short exposure times and cytotoxicity endpoints were the most tested, although there was no consensus on drug concentrations. Extensive analysis highlighted the lack of agreement on control compounds for in vitro DILI assessment. Following comprehensive in vitro and clinical data analysis together with input from the expert committee, an evidence-based consensus-driven list of 10 positive and negative control drugs for validation of in vitro models of DILI is proposed. Prediction of human toxicity early in the drug development process remains a major challenge, necessitating the development of more physiologically relevant liver models and careful selection of drug-induced liver injury (DILI)-positive and -negative control drugs to better predict the risk of DILI associated with new drug candidates. Thus, this systematic study has crucial implications for standardizing the validation of new in vitro models of DILI. By establishing a consensus-driven list of positive and negative control drugs, the study provides a scientifically justified framework for enhancing the consistency of preclinical testing, thereby addressing a significant challenge in early hepatotoxicity identification. Practically, these findings can guide researchers in evaluating safety profiles of new drugs, refining in vitro models, and informing regulatory agencies on potential improvements to regulatory guidelines, ensuring a more systematic and efficient approach to drug safety assessment.

2 November 2022 in Cancers
Verified
Journal Article
Open access
PDF file
JPJose Maria Pinazo
Jose Maria Pinazo
MGMiren Garcia-Cortes
Miren Garcia-Cortes
Antonio Segovia-ZafraAntonio Segovia-Zafra
Antonio Segovia-Zafra
Mª Isabel LucenaMª Isabel Lucena
Mª Isabel Lucena
RARaul J. Andrade
Raul J. Andrade
Recreational or aesthetic drug use is a distinctive behavior of humans, principally attested in the last century. It is known that recreational and illegal drugs are major contributors to the universal morbidity rate worldwide. Many of these substances have a well-established hepatotoxic potential, causing acute or chronic liver injury, liver fibrosis and cirrhosis, but their implications for hepatocellular carcinoma or other varieties of liver tumors are little known. In this article, we perform an extensive literature review, aiming to provide updated information about recreational drug use and the risk of developing liver tumors. Khat use and pyrrolizidine alkaloid consumption (present in some natural plants) have been linked to liver cirrhosis. Kava intake is associated with different liver tumors in animal models but not in humans. Cannabis’ potential to accelerate liver fibrosis in chronic hepatitis is controversial according to the existing data. Cigarette smoking is an important contributor to hepatocellular carcinoma, and anabolic androgen steroids are well-defined causes of a variety of liver cancers and other hepatic tumors. Long-term follow-up studies of subjects who have developed injuries in association with the use of recreational drugs are warranted so as to better define the risk of developing hepatocellular carcinoma in association with these substances and, thus, to implement health care policies to combat this preventable cause of cancer.

25 March 2025 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
RSRomina Lorena de Los Santos‐Fernández
Romina Lorena de Los Santos‐Fernández
Antonio Segovia-ZafraAntonio Segovia-Zafra
Antonio Segovia-Zafra
GPGuillermo Paz‐López
Guillermo Paz‐López
GMGonzalo Matilla‐Cabello
Gonzalo Matilla‐Cabello
HNHao Niu
Hao Niu
IMInmaculada Medina‐Cáliz
Inmaculada Medina‐Cáliz

15 November 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Marina Villanueva-PazMarina Villanueva-Paz
Marina Villanueva-Paz
HNHao Niu
Hao Niu
Antonio Segovia-ZafraAntonio Segovia-Zafra
Antonio Segovia-Zafra
IMInmaculada Medina-Caliz
Inmaculada Medina-Caliz
JSJudith Sanabria-Cabrera
Judith Sanabria-Cabrera
IAIsmael Alvarez
Ismael Alvarez
Drug-induced liver injury (DILI) encompasses the unexpected damage that drugs can cause to the liver. DILI may develop in the context of an immunoallergic syndrome with cutaneous manifestations, which are sometimes severe (SCARs). Nevirapine, allopurinol, anti-epileptics, sulfonamides, and antibiotics are the most frequent culprit drugs for DILI associated with SCARs. Interestingly, alleles HLA-B*58:01 and HLA-A*31:01 are associated with both adverse reactions. However, there is no consensus about the criteria used for the characterization of liver injury in this context, and the different thresholds for DILI definition make it difficult to gain insight into this complex disorder. Moreover, current limitations when evaluating causality in patients with DILI associated with SCARs are related to the plethora of causality assessment methods and the lack of consensual complementary tools. Finally, the management of this condition encompasses the treatment of liver and skin injury. Although the use of immunomodulant agents is accepted for SCARs, their role in treating liver injury remains controversial. Further randomized clinical trials are needed to test their efficacy and safety to address this complex entity. Therefore, this review aims to identify the current gaps in the definition, diagnosis, prognosis, and management of DILI associated with SCARs, proposing different strategies to fill in these gaps.

24 March 2026 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
GMGonzalo Matilla-Cabello
Gonzalo Matilla-Cabello
ÁRÁngela Remesal-Doblado
Ángela Remesal-Doblado
MCMuazzez Celebi-Cinar
Muazzez Celebi-Cinar
AGAna Bodoque García
Ana Bodoque García
FMFatma Betul Metin
Fatma Betul Metin
Marina Villanueva-PazMarina Villanueva-Paz
Marina Villanueva-Paz
Idiosyncratic drug-induced liver injury (iDILI) is a rare, dose-independent and unpredictable adverse reaction occurring at therapeutic drug exposure, and it presents a significant challenge for drug development and patient safety. Despite extensive research, genetic susceptibility to iDILI remains poorly understood. We conducted a comprehensive systematic study of 139 human genetic studies to identify and characterize genetic polymorphisms associated with increased risk or protection against iDILI. Our study included candidate gene studies and genome-wide association studies (GWAS), encompassing 83 risk and 25 protective genes, with NAT2, HLA-B, and SLCO1B1 among the most frequently reported. We performed functional enrichment analyses using KEGG and Gene Ontology, revealing key biological pathways related to immune response, xenobiotic metabolism, and bile secretion. To enhance data accessibility and interpretation, we developed iDILInet, a publicly available web application that enables interactive exploration and network-based visualization of iDILI-associated gene-variant-drug relationships, enriched with liver-specific expression data from the Human Protein Atlas (HPA). Our work provides a novel integrative resource that supports ongoing efforts in precision medicine and pharmacogenomics and represents a significant advancement in implementing living systematic reviews in toxicogenomics.